Goldman Sachs’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$17.1M Buy
608,800
+368,800
+154% +$9.82M ﹤0.01% 2582
2025
Q4
$5.98M Sell
240,000
-348,300
-59% -$8.78M ﹤0.01% 3587
2025
Q3
$15M Buy
588,300
+438,300
+292% +$10.8M ﹤0.01% 2556
2025
Q2
$3.64M Sell
150,000
-100,000
-40% -$2.33M ﹤0.01% 3709
2025
Q1
$6.33M Sell
250,000
-176,000
-41% -$4.61M ﹤0.01% 3126
2024
Q4
$11.3M Sell
426,000
-408,500
-49% -$11.1M ﹤0.01% 2675
2024
Q3
$24.2M Buy
834,500
+430,000
+106% +$12.5M ﹤0.01% 1894
2024
Q2
$11.3M Sell
404,500
-82,000
-17% -$2.26M ﹤0.01% 2383
2024
Q1
$13.5M Sell
486,500
-958,200
-66% -$26.6M ﹤0.01% 2187
2023
Q4
$41.6M Buy
1,444,700
+766,500
+113% +$23.2M 0.01% 1309
2023
Q3
$22.5M Sell
678,200
-129,500
-16% -$4.58M ﹤0.01% 1691
2023
Q2
$29.6M Buy
807,700
+82,000
+11% +$3.19M 0.01% 1518
2023
Q1
$29.6M Sell
725,700
-1,129,100
-61% -$48.8M 0.01% 1456
2022
Q4
$95M Sell
1,854,800
-98,100
-5% -$4.7M 0.02% 745
2022
Q3
$85.5M Buy
1,952,900
+18,400
+1% +$894K 0.02% 770
2022
Q2
$101M Sell
1,934,500
-104,800
-5% -$5.34M 0.03% 668
2022
Q1
$106M Sell
2,039,300
-151,100
-7% -$7.84M 0.02% 731
2021
Q4
$129M Sell
2,190,400
-35,600
-2% -$1.76M 0.03% 665
2021
Q3
$95.7M Buy
2,226,000
+91,600
+4% +$4.06M 0.02% 777
2021
Q2
$83.6M Buy
2,134,400
+870,300
+69% +$33.8M 0.02% 852
2021
Q1
$45.8M Buy
1,264,100
+906,600
+254% +$32.2M 0.01% 1235
2020
Q4
$13.2M Buy
357,500
+121,720
+52% +$4.46M ﹤0.01% 2231
2020
Q3
$8.21M Buy
+235,780
New +$8.27M ﹤0.01% 2495
2020
Q1
Sell
-118,997
Closed -$4.42M 5471
2019
Q4
$4.42M Hold
118,997
﹤0.01% 3056
2019
Q3
$4.06M Sell
118,997
-3,134,701
-96% -$114M ﹤0.01% 3020
2019
Q2
$134M Buy
3,253,698
+2,583,881
+386% +$103M 0.04% 526
2019
Q1
$27M Sell
669,817
-555,247
-45% -$22.2M 0.01% 1614
2018
Q4
$50.7M Buy
1,225,064
+672,136
+122% +$27.9M 0.02% 1081
2018
Q3
$23.1M Buy
552,928
+13,069
+2% +$503K 0.01% 1816
2018
Q2
$18.6M Sell
539,859
-238,836
-31% -$8.16M 0.01% 1932
2018
Q1
$26.2M Sell
778,695
-466,501
-37% -$16M 0.01% 1630
2017
Q4
$42.8M Sell
1,245,196
-477,462
-28% -$16.3M 0.01% 1405
2017
Q3
$58.3M Sell
1,722,658
-1,907,423
-53% -$61.3M 0.01% 1167
2017
Q2
$116M Buy
3,630,081
+1,068,229
+42% +$33.7M 0.03% 677
2017
Q1
$83.2M Sell
2,561,852
-2,486,492
-49% -$78.4M 0.02% 880
2016
Q4
$156M Buy
5,048,344
+1,733,619
+52% +$52.9M 0.04% 510
2016
Q3
$107M Sell
3,314,725
-1,205,143
-27% -$40.3M 0.03% 676
2016
Q2
$151M Sell
4,519,868
-931,525
-17% -$29.7M 0.05% 457
2016
Q1
$153M Buy
5,451,393
+3,016,653
+124% +$86.2M 0.05% 453
2015
Q4
$74.6M Sell
2,434,740
-2,033,377
-46% -$64M 0.02% 840
2015
Q3
$133M Buy
4,468,117
+1,765,239
+65% +$56.6M 0.04% 478
2015
Q2
$86M Sell
2,702,878
-5,028,423
-65% -$164M 0.03% 760
2015
Q1
$255M Buy
7,731,301
+5,522,644
+250% +$176M 0.08% 262
2014
Q4
$65.3M Buy
2,208,657
+634,192
+40% +$18.2M 0.02% 917
2014
Q3
$44.2M Buy
1,574,465
+4,637
+0.3% +$130K 0.01% 1166
2014
Q2
$44.2M Sell
1,569,828
-2,388,891
-60% -$68.1M 0.01% 1196
2014
Q1
$121M Buy
3,958,719
+330,113
+9% +$9.84M 0.04% 538
2013
Q4
$105M Sell
3,628,606
-697,221
-16% -$20.3M 0.03% 609
2013
Q3
$118M Sell
4,325,827
-1,121,245
-21% -$30.5M 0.04% 523
2013
Q2
$145M Buy
+5,447,072
New +$151M 0.06% 392

Other funds holding PFE

Goldman Sachs's PFE Position: Q1 2026 in Review

Goldman Sachs increased its Pfizer (PFE) stake by 18% in Q1 2026, buying an estimated $188M and bringing the position to 47,105,556 shares worth $1.32B. The position accounts for 0.15% of the portfolio, ranked #113.

Goldman Sachs first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.14B in Q1 2016. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Goldman Sachs held 47,105,556 shares of Pfizer worth $1.32B as of Q1 2026.
  • Goldman Sachs bought 7,049,994 Pfizer shares in Q1 2026, an estimated $188M.
  • Pfizer made up 0.15% of Goldman Sachs's portfolio in Q1 2026, its #113 holding.
  • Goldman Sachs first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Pfizer position peaked at $3.14B in Q1 2016.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.